Department of Defense (DOD) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award

The summary for the Department of Defense (DOD) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

Department of Defense (DOD) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award: The Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award supports the preclinical assessment of therapeutics for amyotrophic lateral sclerosis (ALS). The overall goal of this award mechanism is to promote the introduction of improved therapies for ALS by encouraging ALS investigators to undertake preclinical studies of novel and existing agents. The Therapeutic Development Award is restricted to research in ALS. The proposed studies are expected to be empirical in nature and product-driven, but they may have a hypothesis-driven approach provided the focus is on therapeutics. It is anticipated that the agents, and/or data generated from these awards will lead to the advancement of therapeutics for ALS. Please note that the Therapeutic Development Award mechanism is designed to support preclinical testing of therapeutics for ALS. Studies focused on basic science research (i.e., not therapeutic studies) do not meet the intent of the award mechanism. Additionally, clinical trials will not be supported. Therapeutic Development Award proposals are limited to the areas of programmatic interest listed below. Proposals must focus on one or more of these areas to be considered for funding. Proposals that do not focus on at least one of the following areas will be administratively withdrawn. . Development and/or validation of high-throughput screens to define targets with therapeutic potential or identify lead agents for ALS treatment and be an asset for the ALS research community; . Development, modification, and/or validation of preclinical model systems in order to assess by pharmacological and/or pharmacokinetic testing lead compounds and potential therapeutics in addition to serving as an improved tool for the ALS research community; . Development of pharmacologic agents through Adsorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) phase; . Design and implementation of full-scale, pilot current Good Manufacturing Practice (cGMP) production of therapeutics and/or delivery systems for use in advanced preclinical and initial clinical trials; . Development of pharmacologic agents to the Investigational New Drug (IND) stage in order to initiate Phase 1 clinical trials after the awards completion. Proposals must include preliminary data relevant to the phase(s) of the preclinical development process covered by the proposed research. The proposal should include a clear statistical plan of analysis if appropriate.